FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4317863025> ?p ?o ?g. }

• W4317863025 endingPage "TPS258" @default.
• W4317863025 startingPage "TPS258" @default.
• W4317863025 abstract "TPS258 Background: Despite the superiority in progression-free survival (PFS) of inhibition of programmed cell death-1 (PD-1) pathway in dMMR/MSI-H as compared to chemotherapy with either anti-vascular endothelial growth factor receptor (VEGFr) or anti-epithelial growth factor receptor (EGFr) antibodies in mCRC, more pts had progressive disease as the best response in the anti-PD1 monotherapy arm (29.4% v 12.3%) with mean PFS of 13.7 mos, with ~45% of pts in the immunotherapy arm progressed at 12 mos (KEYNOTE 177). We hypothesize that dMMR/MSI-H mCRC pts may be more effectively treated with the combination of PD-1 pathway blockade and mFOLFOX6/bevacizumab (bev) rather than with anti-PD-1 therapy (atezo) alone. Preclinical work demonstrated synergistic effects between anti-PD-1/anti-VEGF and between oxaliplatin/anti-PD-1 in murine CRC models and phase II data, which showed activity of anti-PD-1/anti-VEGF in chemotherapy refractory colon cancer. A recent randomized trial subgroup analysis of 8 pts with dMMR metastatic colon cancer treated with FOLFOXIRI+bev+atezo, with the first patient having progression ~16 mos (AtezoTRIBE). Additionally, in other solid tumor malignancies, anti-PD1 plus anti-VEGFr (i.e., HCC and RCC) as well as anti-PD1 plus chemotherapy (i.e., gastric and esophageal cancers) combinations are standard first-line treatments. Methods: The redesigned COMMIT study was reactivated on 1/29/2021 as a two-arm prospective phase III open-label trial randomizing (1:1) mCRC dMMR/MSI-H to atezo monotherapy v mFOLFOX6/bev+atezo combination. Assuming our control arm, atezo monotherapy (48% PFS at 24 mos as assessed by site investigator), we have 80% power to detect a hazard ratio of 0.6 (equivalent to 64.4% PFS at 24 mos) with alpha 0.025 one-sided. Stratification factors include BRAFV600E status, metastatic site, and prior adjuvant CRC therapy. Secondary endpoints include OS, objective response rate, safety profile, disease control rate, and duration of response. Health-related quality of life is an exploratory objective. Archived tumor tissue and blood samples will be collected for correlative studies. Key inclusion criteria are: mCRC without prior chemotherapy for advanced disease; dMMR tumor determined by local CLIA-certified IHC assay (MLH1/MSH2/MSH6/PMS2) or MSI-H by local CLIA-certified PCR or NGS panel; and measurable disease per RECIST. Enrollment actively continues to the target accrual of 211 patients randomized between the two immunotherapy arms. Clinical trial: NCT02997228. Support: U10CA180868, -180822, -180888, UG1CA189867, U24CA196067; Genentech, Inc. Clinical trial information: NCT05080673 ." @default.
• W4317863025 created "2023-01-25" @default.
• W4317863025 creator A5015750678 @default.
• W4317863025 creator A5020154592 @default.
• W4317863025 creator A5033680753 @default.
• W4317863025 creator A5037149615 @default.
• W4317863025 creator A5044225007 @default.
• W4317863025 creator A5048654505 @default.
• W4317863025 creator A5048973199 @default.
• W4317863025 creator A5049175137 @default.
• W4317863025 creator A5055013606 @default.
• W4317863025 creator A5057918523 @default.
• W4317863025 creator A5060040445 @default.
• W4317863025 creator A5060977002 @default.
• W4317863025 creator A5063192858 @default.
• W4317863025 creator A5067934179 @default.
• W4317863025 creator A5070980712 @default.
• W4317863025 creator A5085949674 @default.
• W4317863025 date "2023-02-01" @default.
• W4317863025 modified "2023-10-18" @default.
• W4317863025 title "NRG-GI004/SWOG-S1610: Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) study—A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer (mCRC)." @default.
• W4317863025 doi "https://doi.org/10.1200/jco.2023.41.4_suppl.tps258" @default.
• W4317863025 hasPublicationYear "2023" @default.
• W4317863025 type Work @default.
• W4317863025 citedByCount "0" @default.
• W4317863025 crossrefType "journal-article" @default.
• W4317863025 hasAuthorship W4317863025A5015750678 @default.
• W4317863025 hasAuthorship W4317863025A5020154592 @default.
• W4317863025 hasAuthorship W4317863025A5033680753 @default.
• W4317863025 hasAuthorship W4317863025A5037149615 @default.
• W4317863025 hasAuthorship W4317863025A5044225007 @default.
• W4317863025 hasAuthorship W4317863025A5048654505 @default.
• W4317863025 hasAuthorship W4317863025A5048973199 @default.
• W4317863025 hasAuthorship W4317863025A5049175137 @default.
• W4317863025 hasAuthorship W4317863025A5055013606 @default.
• W4317863025 hasAuthorship W4317863025A5057918523 @default.
• W4317863025 hasAuthorship W4317863025A5060040445 @default.
• W4317863025 hasAuthorship W4317863025A5060977002 @default.
• W4317863025 hasAuthorship W4317863025A5063192858 @default.
• W4317863025 hasAuthorship W4317863025A5067934179 @default.
• W4317863025 hasAuthorship W4317863025A5070980712 @default.
• W4317863025 hasAuthorship W4317863025A5085949674 @default.
• W4317863025 hasConcept C121608353 @default.
• W4317863025 hasConcept C126322002 @default.
• W4317863025 hasConcept C143998085 @default.
• W4317863025 hasConcept C2775949291 @default.
• W4317863025 hasConcept C2776694085 @default.
• W4317863025 hasConcept C2777701055 @default.
• W4317863025 hasConcept C2777802072 @default.
• W4317863025 hasConcept C2780030458 @default.
• W4317863025 hasConcept C2780962732 @default.
• W4317863025 hasConcept C526805850 @default.
• W4317863025 hasConcept C71924100 @default.
• W4317863025 hasConceptScore W4317863025C121608353 @default.
• W4317863025 hasConceptScore W4317863025C126322002 @default.
• W4317863025 hasConceptScore W4317863025C143998085 @default.
• W4317863025 hasConceptScore W4317863025C2775949291 @default.
• W4317863025 hasConceptScore W4317863025C2776694085 @default.
• W4317863025 hasConceptScore W4317863025C2777701055 @default.
• W4317863025 hasConceptScore W4317863025C2777802072 @default.
• W4317863025 hasConceptScore W4317863025C2780030458 @default.
• W4317863025 hasConceptScore W4317863025C2780962732 @default.
• W4317863025 hasConceptScore W4317863025C526805850 @default.
• W4317863025 hasConceptScore W4317863025C71924100 @default.
• W4317863025 hasFunder F4320332161 @default.
• W4317863025 hasFunder F4320332193 @default.
• W4317863025 hasIssue "4_suppl" @default.
• W4317863025 hasLocation W43178630251 @default.
• W4317863025 hasOpenAccess W4317863025 @default.
• W4317863025 hasPrimaryLocation W43178630251 @default.
• W4317863025 hasRelatedWork W1997133872 @default.
• W4317863025 hasRelatedWork W2050348440 @default.
• W4317863025 hasRelatedWork W2051540233 @default.
• W4317863025 hasRelatedWork W2098707609 @default.
• W4317863025 hasRelatedWork W2145753255 @default.
• W4317863025 hasRelatedWork W2316610093 @default.
• W4317863025 hasRelatedWork W2340695374 @default.
• W4317863025 hasRelatedWork W2465617904 @default.
• W4317863025 hasRelatedWork W2545945608 @default.
• W4317863025 hasRelatedWork W1967062665 @default.
• W4317863025 hasVolume "41" @default.
• W4317863025 isParatext "false" @default.
• W4317863025 isRetracted "false" @default.
• W4317863025 workType "article" @default.